Table 2

Clinical characteristics of EVI1+ patients in relation to clinical parameters, morphology, cytogenetics, and molecular characteristics of 534 patients with newly diagnosed AML

No. of EVI1 patientsNo. of EVI1+ patients (%)P
Sex*.19
    Male24225 (11)
    Female25116 (17)
Age, y*.22
    Younger than 3511714 (11)
    Between 35 and 5016612 (15)
    Older than 5021015 (15)
HOVON protocol*
    04A493 (6)>.99
    04408 (17).50
    2920312 (6).32
    3250 (0)>.99
    4214011 (7).85
    43557 (11).54
FAB*
    M0162 (11).64
    M11046 (5).42
    M21236 (5).18
    M3241 (4).71
    M48213 (14).11
    M510410 (9).85
    M671 (12).47
    Mx332 (6)>.99
Cytogenetic abnormalities*
    −5/5q−163 (16).23
    −7/7q−2113 (38)<.001
    3q2628 (80)<.001
    t(9;22)(q34;q11)11 (50).17
    t(11q23)88 (50)<.001
    t(15;17)(q22;q21)211 (5).71
    t(8;21)(q22;q22)390 (0).039
    inv(16)/t(16;16)370 (0).065
    +8222 (8).71
    +2132 (40).05
    t(6;9)(p23;q34)60 (0)>.99
    Complex201 (5)>.99
    Other656 (8)>.99
    Normal2186 (3)<.001
    ND202 (9)>.99
Cytogenetic risk*
    Favorable891 (1).23
    Intermediate34717 (5)<.001
    Unfavorable5723 (29)<.001
Molecular abnormalities*
    FLT3 ITD1355 (4).027
    FLT3 TKD431 (2).23
    KRAS50 (0)>.99
    NRAS405 (11).57
    CEBPA431 (2).23
    NPM11582 (1)<.001
WBC count, ×109/L, mean; SD52; 6345; 49.18
Platelet count, ×109/L, mean; SD72; 101165; 241.01
Blast % in BM, mean; SD61; 2761; 24.38
  • FAB indicates French-American-British classification; BM, bone marrow; FLT3 ITD, internal tandem duplication of the FLT3 gene; FLT3 TKD, a mutation in tyrosine kinase domain of the FLT3 gene; Mx, FAB not available; ND, not determined; —, not applicable; and SD, standard deviation.

  • * P values were calculated using the 2-tailed chi-square test.

  • All patients with a specific abnormality were considered irrespective of the presence of additional abnormalities.

  • P values were calculated using 2-tailed t test.